摘要
高胆固醇血症是冠状动脉粥样硬化性疾病的重要危险因素之一,血脂控制良好可降低心血管疾病患者心血管事件的发生风险。他汀类药物是降脂治疗的基石,但仍有降脂效果未达标的情况发生,并可导致多种不良反应。前蛋白转化酶枯草溶菌素9(PCSK9)单克隆抗体是新型降脂药物。家族性高脂血症或心血管疾病患者在应用他汀类药物的基础上,联合PCSK9单克隆抗体可进一步降低低密度脂蛋白胆固醇水平,减少并发症发生。目前Evolocumab和Alirocumab两种PCSK9单克隆抗体已被批准应用于临床。
Hypercholesterolemia is one of the significant risks causing coronary atherosclerotic disease.It can reduce the risk of cardiovascular events to control blood lipids well.Although statins are the foundation of lipid-lowering therapy,there are still patients whose lipid level cannot reach the standard,and many adverse reactions are caused.The proprotein convertase subtilisin/kexin type 9(PCSK9)monoclonal antibody is a recently developed lipid-lowering drug.The combination of statins with PCSK9 monoclonal antibodies can further reduce the low-density lipoprotein cholesterol levels and the occurrence of complications for patients with familial hyperlipidemia or cardiovascular disease.Currently,two kinds of PCSK9 monoclonal antibodies,Evolocumab and Alirobumab,have been approved for the clinical application.
作者
齐静
马淑梅
QI Jing;MA Shumei(Department Three of Cardiovascular Medicine,Shengjing Hospital Affiliated to China Medical University,Shenyang 110001,China;Department One of Cardiovascular Medicine,Shengjing Hospital Affiliated to China Medical University,Shenyang 110001,China)
出处
《医学综述》
2019年第17期3497-3501,3507,共6页
Medical Recapitulate
